| Name | Title | Contact Details |
|---|
St. Joseph of the Pines Health System is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. St. Joseph of the Pines Health System is based in Newark, NJ. You can find more information on St. Joseph of the Pines Health System at www.sjp.org
HealthPRO Rehabilitation Management Services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Cockeysville, MD. To find more information about HealthPRO Rehabilitation Management Services, please visit www.healthpro-rehab.com
Volpara Health provides an advanced AI software platform that enables a high-quality, optimized and personalized cancer screening experience. From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyzes information to better understand a patient`s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities. More than thirteen million women across 39 countries have had their breast density assessed by Volpara. The company`s software is installed in approximately 2000 leading facilities worldwide, including top cancer centers in the United States. Volpara Health`s technology has been the subject of more than 300 publications. The Volpara Breast Health Platform is supported by numerous patents, trademarks, and regulatory registrations, including FDA clearance and CE marking.
Wesana Health helps people transcend barriers in mental health and performance. We innovate in care development through our therapies and patent-pending protocols, and in care delivery through activating a new multidisciplinary, technology-supported clinical model.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.